DEV Community

Me-Time Support
Me-Time Support

Posted on

IBS and the Gut-Brain Axis: Why Anti-Inflammatory Beats Anti-Spasmodic

IBS affects 10-15% of the global population. It's not "just stress" — it's a complex disorder of the gut-brain axis with measurable biological markers.

The IBS Triad

IBS has three interconnected drivers:

  1. Visceral hypersensitivity — the gut's pain threshold is lowered
  2. Dysmotility — too fast (diarrhea) or too slow (constipation)
  3. Gut-brain axis dysfunction — bidirectional communication breakdown

Traditional treatment targets ONE of these. Anti-spasmodics for pain. Loperamide for diarrhea. Fiber for constipation. None address the underlying inflammation driving all three.

The Micro-Inflammation Discovery

Recent research shows IBS patients have measurable micro-inflammation:

  • Increased mast cells in intestinal mucosa
  • Elevated pro-inflammatory cytokines
  • Altered microbiome composition
  • Low-grade NF-κB activation

This isn't "all in your head." It's measurable, biological, and treatable.

Ginger: The Multi-Target Approach

IBS Problem Ginger Mechanism
Bloating Prokinetic — accelerates gastric emptying
Visceral pain 5-HT3 antagonism (same target as alosetron)
Spasm Smooth muscle relaxation
Micro-inflammation Intestinal NF-κB inhibition
Anxiety component BDNF + cortisol modulation (gut-brain axis)
Dysbiosis Prebiotic effect on microbiome diversity

Six mechanisms from one compound system, addressing all three drivers simultaneously.

The Product

INTI — zero sugar, organic ginger + turmeric + black pepper. The prokinetic effect alone makes it worth trying for IBS bloating. The anti-inflammatory and gut-brain effects are bonuses.


When a disease has three drivers, you need a solution that addresses all three. Not three separate drugs for each one.

Top comments (0)